Overview
INDV market data
Price History
INDV price chart
Valuation & Profitability
- P/E (TTM)
- 12.79 Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
- Forward P/E
- — P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
- EPS (TTM)
- $1.64 Diluted earnings per share over the trailing twelve months.
- Beta
- 0.58 Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
- Dividend Yield
- — Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
- Profit Margin
- 26.7% Net income divided by revenue. Comparable within a sector, less so across sectors.
- 52w range
- $21.83 – $42.81 Lowest and highest closing prices over the past 52 weeks.
- Analyst Target
- — Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.
Display-only. Refreshed once per symbol per 24 hours · market cap $4.5B · P/B 49.56 · P/S 3.41.
Company News
Barclays Maintains Overweight on Indivior Pharmaceuticals, Lowers Price Target to $43Benzinga · Aug 5, 2026, 12:47 PM
Top 3 Health Care Stocks You'll Regret Missing This QuarterBenzinga · Aug 4, 2026, 10:04 AM
Why Supernus Pharmaceuticals Stock Topped the Market TodayThe Motley Fool · Aug 3, 2026, 11:15 PM
Supernus to Combine with Indivior To Form CNS Biopharmaceutical Leader with Potential $2 Billion in RevenueBenzinga · Aug 3, 2026, 2:44 PM
8-K filing — Indivior Pharmaceuticals, Inc. (INDV)SEC EDGAR · Aug 3, 2026, 12:32 PM
Indivior Pharmaceuticals Raises FY2026 Sales Guidance from $1.215B-$1.285B to $1.295B-$1.365B vs $1.245B EstBenzinga · Aug 3, 2026, 10:45 AM
Supernus Pharmaceuticals To Merge With Indivior Pharmaceuticals; SUPN Stockholders Will Receive 1.5401 Shares Of INDV Per SUPN Share; Indivior Stockholders Will Receive One-Time Special Cash Dividend Of $1B Immediately Prior To Closing; Expected To Generate $125M In Annual Cost SynergiesBenzinga · Aug 3, 2026, 10:35 AM
Indivior Q2 Adj. EPS $1.15 Beats $0.87 Estimate, Sales $343.000M Beat $307.550M EstimateBenzinga · Aug 3, 2026, 10:35 AM
Indivior to Report Second Quarter 2026 Financial Results and Host WebcastGlobenewswire Inc · Jul 23, 2026, 2:15 PM
Barclays Initiates Coverage On Indivior Pharmaceuticals with Overweight Rating, Announces Price Target of $46Benzinga · Jun 18, 2026, 12:55 PM